Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + anlotinib + 2-cycle platinum chemotherapy for advanced non-small cell lung cancer
ChiCTR2200061448Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Hainan Medical University
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Second Affiliated Hospital of Hainan Medical University. Primary endpoints: Progression-free survival and Overall response rate. Started Jun 2021; status: recruiting.
02
Drugs
tislelizumabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200061448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061448.